Results 81 to 90 of about 54,977 (304)

Expression of ITGB1 in PDAC tissues obtained by EUS-FNAB.

, 2022
(A, B) Representative immunohistochemical staining of PDAC tissue samples using anti-ITGB1 antibody showing (A) high and (B) low expression of ITGB1. Arrows, PDAC cells; arrowheads, normal pancreatic duct epithelium. Magnification: ×400.
Mutsuo Furihata (432061), Keisuke Taniuchi (325867), Masahiko Sakaguchi (6804359), Seiji Naganuma (3461909), Makoto Ueno (764555), Takuhiro Kosaki (12231653), Tomoyuki Yokose (153369), Reiko Yoshioka (480628), Mitsunari Ogasawara (12231650)   +8 more
core   +1 more source

Multi‐regional Organoid Biobank Reveals FAK‐ACSL1‐Driven Doxorubicin‐Resistance and Predictive Biomarkers in Breast Cancer

Advanced Science, EarlyView.
This study established a high‐quality organoid biobank derived from 68 tumor sites across 50 Chinese patients, elucidated the drug sensitivity‐based molecular subtyping in breast cancer, and revealed a novel mechanism of drug resistance mediated by the FAK‐ACSL1 pathway.
Hao Xu, Zhijun Qin, Jiapeng Yang, Baoyuan Zhang, Manqing Cao, Peng Wang, Zaiqi Wang, Jinghui Cheng, Lei Wang, Hong Liu, Hui Yang   +10 more
wiley   +1 more source

Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment

Advanced Science, EarlyView.
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo, Yijuan Wang, Dengwang Chen, Yinghan Zhang, Yi Shuai, Hualiang Yao, Tao Jiang, Hang Jiang, Ming Zhong, Xiangeng Wang, Ziwei Wang, Chenchen Xu, Ajay Goel, Hoi Tang MA, Feng Gao, Xin Wang   +15 more
wiley   +1 more source

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

Advanced Science, EarlyView.
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu, Jiaxuan Chen, Abdechakour Elkihel, Wenjun Lan, Nicolas Fraunhoffer, Dandan Zhu, Baoping Lian, Christina Galanakou, Zhancun Bian, Xi Liu, Odile Gayet, Loic Moubri, Julie Aglietti Roques, Vikash Reebye, Nagy Habib, Xiaoxuan Liu, Nelson Dusetti, Juan Lucio Iovanna, Ling Peng   +18 more
wiley   +1 more source

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC

PLOS ONE, 2020
Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches. Targeted therapies could serve as effective treatments to enhance the clinical response rate.
Matthew Brown, Wanbin Zhang, Deyue Yan, Rajath Kenath, Le Le, He Wang, Daniel Delitto, David Ostrov, Keith Robertson, Chen Liu, Kien Pham   +10 more
openaire   +4 more sources

Weak to moderate and heterogeneous CDX2 expression in metastatic PDAC.

, 2014
A–B, Metastatic PDAC in peripancreatic lymph nodes. C–D, Metastatic PDAC in lung. E, Metastatic PDAC in liver. F, Metastatic colonic adenocarcinoma in liver served as a control.
Amad Awadallah (516772), Wenbin Xiao (343825), Wei Xin (306299), Hong Hong (5657557), Lan Zhou (407521)   +4 more
core   +1 more source

MiR-497 suppressed PDAC cells proliferation.

, 2014
Proliferation was analyzed by CCK-8 assay. (A, B) Transfection with miR-497 mimics suppressed PDAC cells proliferation in AsPC-1 and BxPC-3 cells, respectively.
Tian-Xiao Wang (494198), Lian-Fang Zheng (542436), Tai-Ping Zhang (501309), Hong Shu (542437), Yu-Pei Zhao (501310), Jian-Wei Xu (542434), Lei You (542435)   +6 more
core   +1 more source

Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
IGF2BP1 promotes gemcitabine resistance in pancreatic cancer by stabilizing m6A‐modified FTH1 transcripts and protecting them in stress granules, thereby suppressing ferroptosis. Pharmacological inhibition of IGF2BP1 disrupts this protective pathway, restores ferroptotic sensitivity, and enhances gemcitabine efficacy in resistant tumors.
Ying‐Qin Zhu, Yue Huang, Jing‐Yuan Ye, Si‐Yuan Lu, Zhi‐De Liu, Ming‐Jian Ma, De‐Liang Fang, Zi‐Yi Zhao, Jin‐Zhao Xie, Jiao Chen, Xiao‐Yu Yin   +10 more
wiley   +1 more source

Serum levels of BAFF and APRIL in patients with PDAC.

, 2013
(A) Serum levels of BAFF were determined in patients with PDAC (n = 44) and in healthy subjects (n = 44). (B) Serum levels of APRIL were determined in patients with PDAC (n = 44) and in healthy subjects (n = 44).
Bunzo Matsuura (429489), Hirofumi Yamanishi (442548), Morikazu Onji (429490), Mitsuhito Koizumi (442547), Tetsuji Kobata (442550), Yoichi Hiasa (156596), Teru Kumagi (43326), Nobuaki Azemoto (442549), Masanori Abe (421879)   +8 more
core   +1 more source

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

Advanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo, Yang Zhao, Xianle Rong, Xingyu Chen, Xiao Wang, Tianyi Liu, Yunfei Xie, Yushu Zou, Pingsen Zhao, Qiang Liu, Fuping You   +10 more
wiley   +1 more source